Invivyd, Inc. (IVVD)
0.9645
+0.06
(+7.15%)
USD |
NASDAQ |
Aug 28, 16:00
0.9959
+0.03
(+3.26%)
After-Hours: 06:31
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 284.29M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -2.58% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 4.471 |
| Price to Book Value | 1.57 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0463 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT. |
| URL | http://www.invivyd.com |
| Investor Relations URL | https://investors.invivyd.com/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT. |
| URL | http://www.invivyd.com |
| Investor Relations URL | https://investors.invivyd.com/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |